Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.47 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.46 |
| ▸ | ITGAL | P20701 | 3/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16364168 | 0.86 | CYP3A4 (0.54) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| Carnosine SCHEMBL22392772 | 0.85 | SLC15A2 (0.63) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| Carnosine SCHEMBL1160796 | 0.85 | SLC15A2 (0.63) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| Carnosine SCHEMBL1161102 | 0.85 | SLC15A2 (0.63) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL18381307 | 0.84 | CYP3A4 (0.52) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL10031610 | 0.84 | SLC6A5 (0.53) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL21089953 | 0.84 | CYP3A4 (0.52) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL16551861 | 0.84 | CYP3A4 (0.52) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| Carnosine SCHEMBL27776508 | 0.84 | SLC15A2 (0.61) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| Carnosine SCHEMBL30129832 | 0.84 | SLC15A2 (0.61) | CYP3A4CYP2D6TSHRCYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093427-B2 | Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-01-10 | — | — | US | disclosed |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | CYP4F2, ACR, CYP4F3 | CYP3A4 179/4885CYP2D6 82/4885TSHR 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.